Company Metrics

• 86.13 P/E
• 3.55 P/S
• 1.91 P/B
• -0.12 EPS
• 43.39% Cash ROIC
• 2.61 Cash Ratio
• 0 / 0% Dividend
• 1.41M Avg. Vol.
• 266.67M Shares
• 11.075B Market Cap.

Company Description

Forest Laboratories, Inc. develops, manufactures, and sells branded and generic forms of ethical drug products. Its principal products include Lexapro for the treatment of depression in adults and adolescents, and generalized anxiety disorder in adults; Namenda for the treatment of Alzheimer's disease; Bystolic for the treatment of hypertension; and Savella for the management of fibromyalgia. The company is also developing various products, including Daxas, which is in Phase III clinical trial for the treatment of chronic obstructive pulmonary disease (COPD); Ceftaroline that has completed Phase II clinical trial for the treatment of community acquired bacterial pneumonia; ceftazidime/NXL104 combination, which is in Phase II clinical trial; and Linaclotide that is in the Phase III clinical trial for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation. In addition, it is developing Aclidinium, which is in the Phase III clinical trial as an inhaled therapy for COPD; LAS100977 that is in Phase II clinical trial for the treatment of asthma and COPD; Cariprazine, which is in Phase III clinical trial for the treatment of schizophrenia, bipolar mania, and other psychiatric conditions; F2695 that is in pre-clinical stage for the treatment of depression; Radiprodil, which is in Phase II clinical trial for the treatment of chronic pain and other central nervous system conditions; and mGLuR1/5 Compounds for the treatment of anxiety, depression, and other CNS conditions. Forest Laboratories, Inc. sells its products through independent distributors to physicians, pharmacies, hospitals, and managed care and other healthcare organizations. The company was founded in 1956 and is based in New York, New York.
less

Forest Laboratories, Inc. develops, manufactures, and sells branded and generic forms of ethical drug products. Its principal products include Lexapro for the treatment of depression in adults and adolescents, and generalized anxiety disorder in adults; Namenda for the treatment of Alzheimer's disease; Bystolic for the treatment of hypertension; and Savella for the management of fibromyalgia. The ...
more

News